Interventional Cardiology Unit, Division of Cardiology, University Hospital of León, Spain.
Department of Cardiology, Hospital Clinic of Barcelona, Spain.
Int J Cardiol. 2017 Sep 15;243:169-173. doi: 10.1016/j.ijcard.2017.05.029. Epub 2017 May 9.
Mitral regurgitation is a common valvular heart disease and its prevalence is expected to increase with population ageing. In the recent years we have witnessed the evolution of several transcatheter devices to correct mitral regurgitation in patients at high-risk for surgery. Most of the evidence of the safety and efficacy of this new therapy comes from MitraClip studies. However, new alternatives have emerged with promising results. The aim of this position paper is to review the current evidence regarding patient selection, expected results and timing for transcatheter mitral valve interventions from the perspective of three European interventional societies.
二尖瓣反流是一种常见的心脏瓣膜病，随着人口老龄化，其患病率预计将会增加。近年来，我们见证了几种经导管装置的发展，这些装置可用于治疗高危手术患者的二尖瓣反流。这种新疗法的安全性和有效性的大部分证据来自于 MitraClip 研究。然而，一些新的替代方案也已出现，且结果很有前景。本文旨在从三个欧洲介入学会的角度，回顾经导管二尖瓣瓣膜介入治疗的患者选择、预期结果和时机的现有证据。
